Race reporting and diversity in US food and drug administration (FDA) registration trials for prostate cancer; 2006–2020

BACKGROUND: There is significant racial disparity in prostate cancer (PCa) in terms of incidence, treatment, and outcomes. Racial diversity and compliance with FDA race reporting guidelines in PCa drug registration trials are unknown. We analyzed racial diversity and race reporting in drug licensing...

Descripción completa

Detalles Bibliográficos
Autores principales: Lythgoe, M. P., Krell, J., Savage, P., Prasad, V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616766/
https://www.ncbi.nlm.nih.gov/pubmed/33859363
http://dx.doi.org/10.1038/s41391-021-00361-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616766/
https://www.ncbi.nlm.nih.gov/pubmed/33859363
http://dx.doi.org/10.1038/s41391-021-00361-0

Ejemplares similares